MRKAd5 HIV-1 gag/pol/nef

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults

CompletedNCT00486408

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-07-31End: 2012-11-30Updated: 2021-10-14

Phase 2

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

CompletedNCT00183261

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2006-03-31End: 2010-10-31Updated: 2021-11-01

Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults

CompletedNCT00413725

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-01-31End: 2012-08-31Updated: 2021-10-15

Related Papers

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Lower Viral Loads and Slower CD4<sup>+</sup>T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02

The Journal of Infectious Diseases2016-03-069 citations

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men

PLoS ONE2015-09-1435 citations

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

2014-02-2088 citations

Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.

2012-04-1910 citations

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

2011-05-11295 citations